Postbiotic for immune support

Composition
ABB C1^® is a synergistic combination of postbiotics based on inactivated Saccharomyces cerevisiae yeast:

• Yeast 1,3/1,6 β-glucans complex: Combination of two sources of yeast cell walls rich in β-1,3/1,6-glucans
• Mineral yeast enriched with selenium and zinc: Inactivated whole cells of yeast enriched with minerals
  
  

Recommended daily dosage: 250-750 mg/day

The immune system relies on several complementary layers that work together to keep the body prepared and responsive.

INNATE IMMUNITY 

Innate immunity is the body’s first line of defence, reacting quickly and non‑specifically through physical barriers and frontline immune cells such as macrophages, phagocytic cells, dendritic cells and NK cells. 

ADAPTIVE IMMUNITY

Adaptive immunity develops more slowly but provides highly specific responses through T cells, B cells and the antibodies they produce, along with a memory component that allows for a more efficient reaction upon re‑exposure. 

TRAINED IMMUNITY

Between these two layers sits trained immunity, a form of innate immune “readiness” in which innate cells become more responsive for a limited period after an initial stimulus. 

Together, these three components form a coordinated system that supports faster responses at the outset and longer‑lasting, more targeted activity over time.

When the immune system encounters a stimulus, naïve CD4+ T cells can develop into different types of T-helper cells, each contributing to immune balance in a distinct way.

Th1 cells help coordinate responses against external challenges by supporting the activity of other immune cells. 
Th2 cells guide responses linked to environmental exposures and contribute to maintaining equilibrium in tissues. 
Th17 cells are involved in defence against specific microbes and participate in inflammatory signalling. 
In parallel, regulatory T cells (Tregs) help maintain immune tolerance by moderating the activity of other T-helper cells to keep the overall response balanced.

These coordinated T‑cell pathways illustrate how the immune system balances activation and regulation to maintain an effective response. In this context, ABB C1^® is particularly relevant, as its composition is designed to interact with these immune layers.

Innate immunity - ABB C1^® enhances phagocytic activity

ABB C1^® has been shown to influence key innate immune functions through controlled ex vivo and in vitro investigation. In these studies, immune cells collected from animals exposed to ABB C1^® demonstrated a notably higher level of phagocytic activity compared with cells exposed to control β‑glucans.

Phagocytosis is a core function of the innate immune system, enabling frontline cells such as monocytes and macrophages to recognise, internalise, and clear unwanted particles. 

ABB C1^® has been shown to markedly increase the proportion of cells displaying phagocytic activity, demonstrating higher activity than yeast and algae β‑glucan reference controls. 

This enhanced activity reflects more efficient early immune engagement, with innate cells becoming better equipped to capture and remove external targets. By strengthening this first‑response mechanism, ABB C1^® makes frontline immune cells more efficient and supports faster and cleaner resolution of pathogens.

Adaptive immunity - ABB C1^® activates the adaptive immune cascade to optimise B-cell response efficiency.

ABB C1^® activates key components of the adaptive immune cascade by engaging both Th1‑driven and regulatory Th2‑associated pathways.

ABB C1^®’s β-glucans complex stimulates strong Th1 signals, notably IFN‑γ and TNF, which are essential for driving B‑cell activation and supporting effective antibody production.

At the same time, this adaptive response is accompanied by regulatory IL‑10 signalling, helping prevent excessive inflammation. It also prevents peaks in IL‑5 and IL‑22, keeping the response away from allergy‑related or autoimmune reactions and favouring repair‑focused pathways.

ABB C1^®’s β‑glucans complex supports fast and effective Th1‑driven pathogen defence, while its Th2‑linked IL‑10/IL-5 response ratio helps maintain inflammatory under control. 

Trained Immunity - ABB C1^® strengthens the body's early defences by priming innate immune cells

ABB C1^®’s β-glucans complex markedly boosts TNF production after secondary stimulation, demonstrating strong trained‑immunity activation. Monocytes primed with ABB C1^® respond more vigorously on day 7 than on day 1, highlighting enhanced early‑defence readiness.

This contributes to an enhanced state of innate readiness, complementing both early defence and longer‑term adaptive coordination to remember and respond more effectively to threats.

ABB C1^® boosts innate defences, supports strong, balanced adaptive immunity and enhances trained immunity. By acting at all three levels of immunity, ABB C1 provides a scientifically grounded, multi‑layered approach to immune support. 

Single-center, randomised, double-blind, placebo-controlled study

Clinical results confirm ABB C1^® activation of trained immunity mechanisms.

Enhancement of T cell immune response to vaccines challenge only seen in ABB C1^® group: stable and time-course increase of T cells.

Supplementation with ABB C1^® demonstrated a more consistent T‑cell response following vaccination, with a stable, time‑dependent increase in CD4⁺, CD3⁺ and CD8⁺ T‑cell subsets observed only in the ABB C1^® group.

Enhancement of humoral response to COVID-19 vaccine: Faster, more intense release of antibodies.

In addition, the ABB C1^® group demonstrated a faster and more pronounced rise in both IgG and IgM levels following the COVID‑19 vaccine, indicating a more coordinated cellular and antibody-mediated immune response compared with placebo.

In volunteers receiving COVID‑19 mRNA vaccines, ABB C1^® was associated with a stronger stimulation of trained immunity compared with placebo. This observation confirms that ABB C1^® supports normal immune function.

ABB C1^® is safe 

No adverse events linked to ABB C1^® supplementation have been recorded.